BioLife Sciences Inc. (OTC: Markets: BLFE) Announced Today It Will Be Expanding Its Newly Formed Orthomolecular Medicine and Natural Health Products Department With a Subsector Dedicated to Cannabidiol (CBD) Sales and Products
BioLife Sciences Inc. (OTC: Markets: BLFE) Announced Today It Will Be Expanding Its Newly Formed Orthomolecular Medicine and Natural Health Products Department With a Subsector Dedicated to Cannabidiol (CBD) Sales and Products
HENDERSON, NV, March 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences (OTCPK: BLFE) (the "Company" or "BioLife) is pleased to announce that it is expanding its recently announced orthomolecular medicine and natural health products department to now include a subsector dedicated to non-psychoactive cannabinoids derived from industrial hemp, including, but not limited to, cannabidiol (CBD) products.
環球新聞網內華達州亨德森2022年3月1日電Via NewMediaWire-BioLife Sciences(OTCPK：BLFE)(以下簡稱“公司”或“BioLife”)高興地宣佈，它正在擴大其最近宣佈的正分子藥物和天然保健品部門，現在包括一個專門研究從工業大麻中提取的非精神活性大麻素的部門，包括但不限於大麻二醇(CBD)產品。
This new subsector will focus on clinical hemp natural health products in addition to non-psychoactive cannabinoid research and development.
這個新的部門將側重於臨牀大麻天然保健品，以及非精神活性大麻素的研究和開發。
BioLife aims to focus on products highlighting hemp's naturally occurring cannabinoids (excluding any psychoactive cannabinoids such as THC), with a focus on CBD, CBG and CBN. The company's focus will be founded in medical products, beverages, creams, salves, efficacious supplements, superfood concentrates, nutraceutical formulations, and advanced orthomolecular and natural health products.
BioLife的目標是專注於突出大麻中天然存在的大麻類化合物的產品(不包括任何具有精神活性的大麻類化合物，如THC)，重點放在CBD、CBG和CBN上。該公司的重點將放在醫療產品、飲料、奶油、藥膏、有效補充劑、超級濃縮食品、營養品配方以及先進的正分子和天然保健品上。
This latest announcement by BioLife is directly founded on the Company's recent acquisition of Health Box LLC, which facilitated the expansion of the Company's scope to micronutrients, medicinal herbal supplements, botanicals and holistic merchandise.
BioLife的這一最新聲明直接建立在該公司最近收購Health Box LLC的基礎上，這筆交易促進了該公司將業務範圍擴大到微量營養素、草藥補充劑、植物製品和整體商品。
CBD usage has steadily increased in the U.S. since 2018, with multiple peer-reviewed studies having confirmed that the cannabinoid may help with a wide variety of ailments and conditions, including, but not limited to, pain, stress, weight loss, anxiety and depression.
自2018年以來，CBD在美國的使用量穩步上升，多項同行評議研究證實，大麻素可能有助於治療各種疾病和狀況，包括但不限於疼痛、壓力、減肥、焦慮和抑鬱。
The Brightfield Group recently announced projections for the hemp CBD industry to continue to expand in 2022, with a projection of nearly 400% growth to $22 billion by the end of the year.
光明集團(Brightfield Group)最近宣佈，預計大麻CBD行業在2022年將繼續擴張，預計到年底將增長近400%，達到220億美元。
CBD growth was driven mainly by ecommerce in 2020, as brick and mortar options were limited due to the COVID-19 pandemic. Consumers previously could purchase CBD products at vitamin shops, beauty retailers or medical practitioner's offices. Even once these brick-and-mortar outlets reopened, e-commerce has maintained a driving force of the industry.
2020年，中央商務區的增長主要是由電子商務推動的，因為新冠肺炎疫情導致實體選擇有限。消費者以前可以在維生素商店、美容零售商或醫生辦公室購買CBD產品。即使這些實體網點重新開張，電商也保持着行業的驅動力。
Nika Jaksic, COO of BioLife Sciences, stated that "We believe CBD sales will continue their strong upward trend with current e-commerce sales soon being joined by consumers returning to brick and mortar options, as the pandemic wanes and disposable incomes continue to rise. CBD and other cannabinoids found in the hemp plant are very helpful supplements, as evidenced by continuous studies highlighting that we haven't even begun to understand all of these healing cannabinoid's abilities and uses."
生物生命科學公司首席運營官尼卡·雅克西奇(Nika Jaksic)表示：“我們相信，隨着流行病的消退和可支配收入的持續增加，目前的電商銷售很快就會加入到消費者的行列中，CBD和其他大麻類化合物的銷售將繼續保持強勁的上升趨勢。CBD和其他在大麻植物中發現的大麻類化合物是非常有用的補充劑，持續的研究表明，我們甚至還沒有開始瞭解所有這些治癒大麻的能力和用途。”
About BioLife Sciences Inc.
關於生物生命科學公司
BioLife Sciences Inc. specializes in moving innovative products from the lab or small-scale production into wider market adoption. Its core business develops, licenses and distributes antimicrobial products and disruptive technology. One of BioLife Sciences' core building block strategies is to develop, partner and assist innovative companies with the commercialization of leading-edge technologies.
生物生命科學公司專門致力於將創新產品從實驗室或小規模生產轉移到更廣泛的市場採用。其核心業務是開發、授權和分銷抗菌產品和破壞性技術。生物生命科學公司的核心戰略之一是開發、合作並協助創新公司將前沿技術商業化。
Disclaimer
免責
The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the ability of the Corporation to complete a qualifying transaction. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurance that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.
本新聞稿中的信息包括有關管理層對未來事件、預期、計劃和前景的看法的某些信息和陳述，這些信息和陳述構成前瞻性陳述。這些陳述是基於受重大風險和不確定因素影響的假設。由於這些風險和不確定因素，以及各種因素的影響，實際結果、預期、成就或業績可能與這些前瞻性陳述中預期和表明的大不相同。本新聞稿中的前瞻性陳述包括但不限於該公司完成合格交易的能力。許多因素都可能導致實際結果與這些前瞻性陳述以及未來結果大不相同。儘管該公司認為前瞻性陳述中反映的預期是合理的，但它不能保證任何前瞻性陳述的預期將被證明是正確的。除非法律另有要求，否則本公司無意更新或修訂任何前瞻性陳述，以反映實際結果，無論是由於新信息、未來事件、假設的變化、影響此類前瞻性陳述的因素的變化或其他原因。
Contact Information:
ir@biolifesciences.com
US & Canada: 1 (833) 919-1037
聯繫方式：
郵箱：ir@biolifesciences.com
美國和加拿大：1(833)919-1037
譯文內容由第三人軟體翻譯。